South Korea Approves Celltrion's COVID-19 Treatment for Use

By Reuters Staff

September 20, 2021

SEOUL (Reuters) - South Korea on Friday approved drugmaker Celltrion Inc's antibody COVID-19 treatment for infected adults in high-risk groups or those with severe symptoms.

Phase III clinical trials showed the monoclonal antibodies significantly reduced deterioration of COVID-19 symptoms to severe levels and shortened recovery, the Ministry of Food and Drug Safety said in a statement on Friday.

The treatment lowered the rate of high-risk patients developing severe symptoms by 72% and shortened recovery by 4.12 days, the ministry said.

Celltrion said in a separate regulatory filing it plans to apply for emergency use approval and permission for the treatment from each country through continuous discussions with each regulatory agency.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....